Urs Weber, Assistant Professor at The University of Colorado Anschutz Medical Campus, shared insights on X regarding new neoadjuvant immunotherapy data presented at ESMO Congress 2026:
“Thought-provoking study presented at ESMO 2026. Can systemic therapy make ‘unresectable’ NSCLC patients resectable? I do think that we should incorporate responsiveness to systemic therapy into our decision-making around surgery somehow.”
Title: Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial
Authors: Martin Reck, Ernest Nadal, Carl M. Gay, Nicolas Girard, Andrea Riccardo Filippi, Linda W. Martin, Cordula Petersen, David A. Cairns, Margarita Majem, Andrea Ardizzoni, Rosa Alvarez Alvarez, Andrew Robinson, Benoit Roch, Arnaud Boyer, Ilaria Attili, Maximilian Diehn, David Kurtz, Ugochinyere A. Emeribe, Ignacio Diaz Perez, Matteo Giaj Levra, Davina Gale, Zhou Zhu, Nefeli Georgoulia, Jonathan Spicer
Find out more:
